Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Details

Ressource 1Download: PMID29097496.pdf (1385.52 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_12A8F7D8B626
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Journal
Haematologica
Author(s)
Voruz S., Cairoli A., Naveiras O., de Leval L., Missiaglia E., Homicsko K., Michielin O., Blum S.
ISSN
1592-8721 (Electronic)
ISSN-L
0390-6078
Publication state
Published
Issued date
01/2018
Peer-reviewed
Oui
Volume
103
Number
1
Pages
e39-e41
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Keywords
Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Biopsy, Combined Modality Therapy, Histiocytic Sarcoma/diagnosis, Histiocytic Sarcoma/drug therapy, Histiocytic Sarcoma/metabolism, Humans, Imatinib Mesylate/administration & dosage, Immunohistochemistry, Immunophenotyping, Male, Molecular Targeted Therapy, Positron Emission Tomography Computed Tomography, Pyridones/administration & dosage, Pyrimidinones/administration & dosage, Retreatment, Symptom Assessment, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
07/11/2017 8:18
Last modification date
20/08/2019 12:40
Usage data